The role of S100P and IMP3 in the cytologic diagnosis of pancreatic adenocarcinoma

Ezzat, Noha; Tahoun, Neveen; Ismail, Yahia M.

doi:10.1016/j.jnci.2016.10.002

Cited by 11 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…That none of 296 analyzed squamous cell carcinomas from other organs of origin were Napsin A positive further emphasizes that this protein is virtually absent in cells with squamous differentiation. It is of note that other investigators have reported Napsin A positivity in 0–10% of pulmonary squamous cell carcinomas in studies analyzing 14–569 tumors [ 16 , 18 , 22 , 24 , 46 – 48 , 50 , 52 , 57 – 59 , 61 – 65 , 67 – 69 ]. One possible reason for a perceived Napsin A positivity in squamous cell carcinomas that we and others encountered is entrapped normal lung tissue with Napsin A positive hyperplastic pneumocytes or Napsin A positive intra-alveolar macrophages between cancer cells [ 3 ].…”

Section: Discussionmentioning

confidence: 91%

“…More than 70 studies have previously analyzed Napsin A expression in tumors by IHC. The studies showed a wide range of Napsin A positivity for each tumor entity, for example, published Napsin A positivity rates ranged from 0% to 100% in adenocarcinoma of the lung [ 11 , 13 , 16 , 18 , 20 , 22 , 24 , 43 – 66 ], 0%–48% in papillary thyroid carcinoma [ 11 , 16 , 18 , 19 , 24 ], 0%–52% in clear cell renal cell carcinoma [ 6 , 13 , 15 – 19 , 22 , 24 ], 0%–17% in small cell carcinoma of the lung [ 13 , 22 , 50 , 61 , 63 ], 0–10% in squamous cell carcinoma of the lung [ 16 , 18 , 22 , 24 , 46 – 48 , 50 , 52 , 57 – 59 , 61 – 65 , 67 – 69 ], 69–100% in clear cell adenocarcinoma of the ovary [ 7 , 19 , 25 , 27 – 32 , 34 ], 72%–97% in papillary renal cell carcinoma [ 6 , 16 – 18 , 20 – 22 ] and 67%–89% in clear cell adenocarcinoma of the endometrium [ 7 , 30 , 70 , 71 ]. The analysis of a large number of different tumor entities under highly standardized conditions enabled us to clarify the relative importance of Napsin A expression across tumor entities and to generate a ranking list according to the expected rate of Napsin A positivity.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Napsin A Expression in Human Tumors and Normal Tissues

Weidemann

Böhle

Contreras³

et al. 2021

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Background: Novel aspartic proteinase of the pepsin family A (Napsin A, TAO1/TAO2) is a functional aspartic proteinase which is involved in the maturation of prosurfactant protein B in type II pneumocytes and the lysosomal protein catabolism in renal cells. Napsin A is highly expressed in adenocarcinomas of the lung and is thus commonly used to affirm this diagnosis. However, studies have shown that other tumors can also express Napsin A.Methods: To comprehensively determine Napsin A expression in normal and tumor tissue, 11,957 samples from 115 different tumor types and subtypes as well as 500 samples of 76 different normal tissue types were evaluable by immunohistochemistry on tissue microarrays.Results: Napsin A expression was present in 16 different tumor types. Adenocarcinoma of the lung (85.6%), clear cell adenocarcinoma of the ovary (71.7%), clear cell adenocarcinoma of the endometrium (42.8%), papillary renal cell carcinoma (40.2%), clear cell (tubulo) papillary renal cell carcinoma (16.7%), endometrial serous carcinoma (9.3%), papillary thyroid carcinoma (9.3%) and clear cell renal cell carcinoma (8.2%) were among the tumors with the highest prevalence of Napsin A positivity. In papillary and clear cell renal cell carcinoma, reduced Napsin A expression was linked to adverse clinic-pathological features (p ≤ 0.03).Conclusion: This methodical approach enabled us to identify a ranking order of tumors according to their relative prevalence of Napsin A expression. The data also show that loss of Napsin A is linked to tumor dedifferentiation in renal cell carcinomas.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Napsin A Expression in Human Tumors and Normal Tissues

Weidemann

Böhle

Contreras³

et al. 2021

Pathol. Oncol. Res.

View full text Add to dashboard Cite

show abstract

“…Moreover, high S100A14 mRNA expression correlated with poor prognosis. S100P is an oncogenic event in many types of tumors, including pancreatic adenocarcinoma, breast cancer and ovarian cancer (Wang et al, 2006;Ezzat et al, 2016;Bai et al, 2018). In ovarian cancer, S100P was shown to be positively correlated with CA125 and poor prognosis (Wang et al, 2015).…”

Section: Discussionmentioning

confidence: 99%

Comprehensive Analysis of the Prognosis and Correlations With Immune Infiltration of S100 Protein Family Members in Hepatocellular Carcinoma

et al. 2021

View full text Add to dashboard Cite

S100 protein family members (S100s) are commonly dysregulated in various tumors including hepatocellular carcinoma (HCC). However, the diverse expression, mutation, prognosis and associations with immune infiltration of S100s in HCC have yet to be analyzed. Herein we investigated the roles of S100s in HCC from the Oncomine, Gene Expression Profiling Interactive Analysis (GEPIA), Human Protein Atlas, Kaplan-Meier Plotter, cBioPortal and TIMER databases. Compared with para-cancer tissues, the expression levels of S100A4/S100A6/S100A10/S100A11/S100A13/S100A14/S100P were higher in HCC tissues, while the expression levels of S100A8/S100A9/S100A12 were decreased in tumor tissues. The mRNA levels of S100A2/S100A7/S100A7A/S100A8/S100A9/S100A11 were correlated with advanced tumor stage. Besides, higher mRNA expressions of S100A6/S100A10/S100A11/S100A13/S100A14/S100P were shown to have shorter overall survival (OS), while higher expression of S100A12 was associated with favorable OS. Further, the mutation rate of S100s was investigated, and the high mutation rate (53%) was associated with shorter OS. Additionally, the expressions of S100s were found to be significantly associated with various immune infiltrating cells. Hence, our results showed that S100A6/S100A10/S100A11/S10012/S100A13/S100A14/S100P may be regarded as new prognostic or therapeutic markers and S100s inhibitors may be helpful in the combination of immunotherapies.

show abstract

“…Some cystic lesions have the potential for malignant neoplastic transformation and are considered malignant precursor for pancreatic ductal adenocarcinoma such as intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs) whereas serous cystic neoplasms (SCNs) are considered benign lesions. Ezzat et al 2016 and Senoo et al 2018 demonstrated sensitivity, and speci city of IMP3 on cytology specimens for PAC were 91.2%, 86.7%, and 87.9%, 100%, respectively, with total accuracy 90.3% and 90.8%, respectively (23)(24). Our ndings concluded that using of combined IMP3 immunohistochemical staining with cytology diagnosis of malignant and benign pancreatic lesions has sensitivity, and speci city of 78.2% and 95.8% with total accuracy 84.3% compared with 64.1%, 100%, and 89% sensitivity, speci city, and total accuracy of cytology diagnosis only, respectively.…”

Section: Eus Approach Is Not Only Minimally Invasive Technique With Low Complications But Also It Provides Usmentioning

confidence: 98%

A Promising Diagnostic Role of Immunohistochemical Expression of Insulin-Like Growth Factor II mRNA Binding Protein 3 (IMP3) in Pancreatic Lesions Using Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) Cytology

Rashed

Nasr

Wasfi

et al. 2022

J Gastrointest Canc

View full text Add to dashboard Cite

Background: Poor prognosis and short survival of patients harboring pancreatic cancer emerge how advanced disease it is. In a trial to achieve the earliest and most accurate diagnosis to manage this progressive disease, we proposed that using endoscopic ultrasound-guided ne needle aspiration (EUS-FNA) with an adjuvant diagnostic immunohistochemical marker would give better diagnostic results.IMP3 has gained recently wide attention, as many studies found that IMP3 has not only diagnostic but also prognostic role in different types of malignancies.Aim of the study: this prospective work is to assess the diagnostic role of EUS-FNA combined with the immunohistochemical expression of IMP3 on different benign and malignant pancreatic lesions.Material and Method: the included pancreatic lesions (n=140) were obtained by EUS-FNA technique and stained for IMP3 immunohistochemically. Para n blocks from patients who underwent excision (n=92) or core biopsies (n=48) were performed for con rming diagnosis.Results: the combined method for diagnosis showed that IMP3 was positive in 78.7%, 91.7%, 100% PAC, Mucinous neoplasm with high grade dysplasia, IPMN with high grade dysplasia, respectively, while almost all benign lesions showed negative IMP3. Also, this method showed sensitivity (78.26%), speci city (95.83%), and accuracy (84.3%).Conclusion: EUS-FNA cytology with IMP3 could be a reliable diagnostic tool especially for assessment of malignant pancreatic lesions.

show abstract

The role of S100P and IMP3 in the cytologic diagnosis of pancreatic adenocarcinoma

Abstract: Both markers were sensitive and specific for diagnosis of PDA. The staining pattern for S100P was easier to evaluate than IMP3.

Cited by 11 publications

References 24 publications

Napsin A Expression in Human Tumors and Normal Tissues

Napsin A Expression in Human Tumors and Normal Tissues

Comprehensive Analysis of the Prognosis and Correlations With Immune Infiltration of S100 Protein Family Members in Hepatocellular Carcinoma

A Promising Diagnostic Role of Immunohistochemical Expression of Insulin-Like Growth Factor II mRNA Binding Protein 3 (IMP3) in Pancreatic Lesions Using Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) Cytology

Contact Info

Product

Resources

About